OBJECTIVE: The goal of this report is to describe the on going strategies, successes, challenges and solutions for recruitment in this multi-center, phase II chemoprevention trial targeting men at high risk for prostate cancer. METHODS: We developed and implemented a multi-center clinical trial in institutions with supportive infrastructure, lead by a recruitment team of experienced and committed physicians and clinical trial staff, implementing multi-media and community outreach strategies to meet recruitment goals. Screening logs were reviewed to identify trends as well as patient, protocol and infrastructure -related barriers impacting accrual and revisions to protocol implemented. RESULTS:Between January 2008 and February 2011 a total of 3547 individuals were prescreened with 94% (n=3092) determined to be ineligible based on diagnosis of cancer or benign biopsy results. Of these, 216 were considered eligible for further screening with 52% (n=113) declining to participate due to patient related factors and 14% (n=29) eliminated due to protocol-related criteria for exclusion. Ninety-four (94) subjects consented to participate with 34% of these subjects (n=74) meeting all eligibility criteria to be randomized to receive study agent or placebo. Across all sites, 99% of the recruitment of subjects in this clinical trial is via physician recruitment and referral with less than 1% responding to other recruitment strategies. CONCLUSION: A contemporary approach to subject recruitment and frequent evaluation is needed to assure responsiveness to emerging challenges to accrual and the evolving scientific literature. A focus on investing on improving systems for physician recruitment may be key to meeting recruitment target in chemoprevention trials.
RCT Entities:
OBJECTIVE: The goal of this report is to describe the on going strategies, successes, challenges and solutions for recruitment in this multi-center, phase II chemoprevention trial targeting men at high risk for prostate cancer. METHODS: We developed and implemented a multi-center clinical trial in institutions with supportive infrastructure, lead by a recruitment team of experienced and committed physicians and clinical trial staff, implementing multi-media and community outreach strategies to meet recruitment goals. Screening logs were reviewed to identify trends as well as patient, protocol and infrastructure -related barriers impacting accrual and revisions to protocol implemented. RESULTS: Between January 2008 and February 2011 a total of 3547 individuals were prescreened with 94% (n=3092) determined to be ineligible based on diagnosis of cancer or benign biopsy results. Of these, 216 were considered eligible for further screening with 52% (n=113) declining to participate due to patient related factors and 14% (n=29) eliminated due to protocol-related criteria for exclusion. Ninety-four (94) subjects consented to participate with 34% of these subjects (n=74) meeting all eligibility criteria to be randomized to receive study agent or placebo. Across all sites, 99% of the recruitment of subjects in this clinical trial is via physician recruitment and referral with less than 1% responding to other recruitment strategies. CONCLUSION: A contemporary approach to subject recruitment and frequent evaluation is needed to assure responsiveness to emerging challenges to accrual and the evolving scientific literature. A focus on investing on improving systems for physician recruitment may be key to meeting recruitment target in chemoprevention trials.
Authors: Jeff Whittle; Kathlyn E Fletcher; Jeffrey Morzinski; Kristyn Ertl; Leslie Patterson; Wayne Jensen; Marilyn M Schapira Journal: J Empir Res Hum Res Ethics Date: 2010-12 Impact factor: 1.742
Authors: Mahmoud A Mohamed; Philipp A Greif; James Diamond; Osama Sharaf; Perry Maxwell; Rodolfo Montironi; Robert A M Young; Peter W Hamilton Journal: BJU Int Date: 2007-04 Impact factor: 5.588
Authors: G J Kelloff; R Lieberman; V E Steele; C W Boone; R A Lubet; L Kopelovitch; W A Malone; J A Crowell; C C Sigman Journal: Eur Urol Date: 1999 Impact factor: 20.096
Authors: C K Allam; D G Bostwick; J A Hayes; M P Upton; G G Wade; G F Domanowski; M A Klein; E A Boling; M M Stilmant Journal: Mod Pathol Date: 1996-07 Impact factor: 7.842
Authors: Nagi B Kumar; Julio Pow-Sang; Kathleen M Egan; Philippe E Spiess; Shohreh Dickinson; Raoul Salup; Mohamed Helal; Jerry McLarty; Christopher R Williams; Fred Schreiber; Howard L Parnes; Said Sebti; Aslam Kazi; Loveleen Kang; Gwen Quinn; Tiffany Smith; Binglin Yue; Karen Diaz; Ganna Chornokur; Theresa Crocker; Michael J Schell Journal: Cancer Prev Res (Phila) Date: 2015-04-14
Authors: Seung Joon Kim; Ernest Amankwah; Shahnjayla Connors; Hyun Y Park; Maria Rincon; Heather Cornnell; Ganna Chornokur; Arig Ibrahim Hashim; Junsung Choi; Ya-Yu Tsai; Robert W Engelman; Nagi Kumar; Jong Y Park Journal: Cancer Prev Res (Phila) Date: 2014-02-05
Authors: Nagi B Kumar; Gwendolyn P Quinn; Mark G Alexandrow; Jhanelle Gray; Michael Schell; Steve Sutton; Eric B Haura Journal: J Clin Trials Date: 2014-09
Authors: Diane St Germain; Andrea M Denicoff; Eileen P Dimond; Angela Carrigan; Rebecca A Enos; Maria M Gonzalez; Kathy Wilkinson; Michelle A Mathiason; Brenda Duggan; Shaun Einolf; Worta McCaskill-Stevens; Donna M Bryant; Michael A Thompson; Stephen S Grubbs; Ronald S Go Journal: J Oncol Pract Date: 2014-01-14 Impact factor: 3.840
Authors: Andrea M Denicoff; Worta McCaskill-Stevens; Stephen S Grubbs; Suanna S Bruinooge; Robert L Comis; Peggy Devine; David M Dilts; Michelle E Duff; Jean G Ford; Steven Joffe; Lidia Schapira; Kevin P Weinfurt; Margo Michaels; Derek Raghavan; Ellen S Richmond; Robin Zon; Terrance L Albrecht; Michael A Bookman; Afshin Dowlati; Rebecca A Enos; Mona N Fouad; Marjorie Good; William J Hicks; Patrick J Loehrer; Alan P Lyss; Steven N Wolff; Debra M Wujcik; Neal J Meropol Journal: J Oncol Pract Date: 2013-10-15 Impact factor: 3.840
Authors: Rebecca Lewis; Rachel Todd; Michelle Newton; Robert J Jones; Caroline Wilson; Jenny L Donovan; Richard T Bryan; Alison Birtle; Emma Hall Journal: Trials Date: 2020-07-08 Impact factor: 2.279
Authors: Sravya Kakumanu; Braden J Manns; Sophia Tran; Terry Saunders-Smith; Brenda R Hemmelgarn; Marcello Tonelli; Ross Tsuyuki; Noah Ivers; Danielle Southern; Jeff Bakal; David J T Campbell Journal: Trials Date: 2019-10-07 Impact factor: 2.279